<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">21536</article-id><article-id pub-id-type="doi">10.7554/eLife.21536</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Tools and Resources</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>One reporter for in-cell activity profiling of majority of protein kinase oncogenes</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-72090"><name><surname>Gudernova</surname><given-names>Iva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72091"><name><surname>Foldynova-Trantirkova</surname><given-names>Silvie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72092"><name><surname>Ghannamova</surname><given-names>Barbora El</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72094"><name><surname>Fafilek</surname><given-names>Bohumil</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72095"><name><surname>Varecha</surname><given-names>Miroslav</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72096"><name><surname>Balek</surname><given-names>Lukas</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72093"><name><surname>Hruba</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72097"><name><surname>Jonatova</surname><given-names>Lucie</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72098"><name><surname>Jelinkova</surname><given-names>Iva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72099"><name><surname>Kunova Bosakova</surname><given-names>Michaela</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72100"><name><surname>Trantirek</surname><given-names>Lukas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72101"><name><surname>Mayer</surname><given-names>Jiri</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-68553"><name><surname>Krejci</surname><given-names>Pavel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0618-9134</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="other" rid="par-11"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Biology, Faculty of Medicine</institution>, <institution>Masaryk University</institution>, <addr-line><named-content content-type="city">Brno</named-content></addr-line>, <country>Czech Republic</country></aff><aff id="aff2"><label>2</label><institution>Central European Institute of Technology, Masaryk University</institution>, <addr-line><named-content content-type="city">Brno</named-content></addr-line>, <country>Czech Republic</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">International Clinical Research Center</institution>, <institution>St. Anne's University Hospital</institution>, <addr-line><named-content content-type="city">Brno</named-content></addr-line>, <country>Czech Republic</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Experimental Biology, Faculty of Sciences</institution>, <institution>Masaryk University</institution>, <addr-line><named-content content-type="city">Brno</named-content></addr-line>, <country>Czech Republic</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Internal Medicine</institution>, <institution>Hematology and Oncology, Masaryk University Hospital</institution>, <addr-line><named-content content-type="city">Brno</named-content></addr-line>, <country>Czech Republic</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewing editor</role><aff id="aff6"><institution>University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>krejcip@med.muni.cz</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>02</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e21536</elocation-id><history><date date-type="received"><day>14</day><month>09</month><year>2016</year></date><date date-type="accepted"><day>31</day><month>01</month><year>2017</year></date></history><permissions><copyright-statement>Â© 2017, Gudernova et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Gudernova et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-21536-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.21536.001</object-id><p>In-cell profiling enables the evaluation of receptor tyrosine activity in a complex environment of regulatory networks that affect signal initiation, propagation and feedback. We used FGF-receptor signaling to identify <italic>EGR1</italic> as a locus that strongly responds to the activation of a majority of the recognized protein kinase oncogenes, including 30 receptor tyrosine kinases and 154 of their disease-associated mutants. The <italic>EGR1</italic> promoter was engineered to enhance <italic>trans</italic>-activation capacity and optimized for simple screening assays with luciferase or fluorescent reporters. The efficacy of the developed, fully synthetic reporters was demonstrated by the identification of novel targets for two clinically used tyrosine kinase inhibitors, nilotinib and osimertinib. A universal reporter system for in-cell protein kinase profiling will facilitate repurposing of existing anti-cancer drugs and identification of novel inhibitors in high-throughput screening studies.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.001">http://dx.doi.org/10.7554/eLife.21536.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>receptor tyrosine kinase</kwd><kwd>protein kinase</kwd><kwd>activity</kwd><kwd>in cell</kwd><kwd>profiling</kwd><kwd>reporter</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Ministry of Education, Youth and Sports of the Czech Republic</institution></institution-wrap></funding-source><award-id>MUNI/A/0810/2016</award-id><principal-award-recipient><name><surname>Gudernova</surname><given-names>Iva</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>SoMoPro II Programme</institution></institution-wrap></funding-source><award-id>G4 target</award-id><principal-award-recipient><name><surname>Foldynova-Trantirkova</surname><given-names>Silvie</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Faculty of Medicine Masaryk University</institution></institution-wrap></funding-source><award-id>Junior grant</award-id><principal-award-recipient><name><surname>Bosakova</surname><given-names>Michaela Kunova</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004410</institution-id><institution>European Molecular Biology Organization</institution></institution-wrap></funding-source><award-id>IG2535</award-id><principal-award-recipient><name><surname>Trantirek</surname><given-names>Lukas</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Marie-Curie Re-integration grant</institution></institution-wrap></funding-source><award-id>ECOPOD</award-id><principal-award-recipient><name><surname>Trantirek</surname><given-names>Lukas</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Ministry of Education, Youth and Sports of the Czech Republic</institution></institution-wrap></funding-source><award-id>KONTAKT II LH15231</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>Grant Agency of Masaryk University</institution></institution-wrap></funding-source><award-id>0071-2013</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution>Ministry of Health of the Czech Republic</institution></institution-wrap></funding-source><award-id>15-33232A</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution>European Union ICRC-ERA-Human Bridge</institution></institution-wrap></funding-source><award-id>316345</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution>Grant Agency of the Czech Republic</institution></institution-wrap></funding-source><award-id>GA17-09525S</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution>Technology Agency of the Czech Republic</institution></institution-wrap></funding-source><award-id>TG02010048</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="par-12"><funding-source><institution-wrap><institution>Ministry of Health of the Czech Republic</institution></institution-wrap></funding-source><award-id>15-34405A</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="par-13"><funding-source><institution-wrap><institution>Ministry of Education, Youth and Sports of the Czech Republic</institution></institution-wrap></funding-source><award-id>CZ.1.05/3.1.00/14.0324</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A new luciferase and fluorescent reporter system enables rapid and efficient in-cell profiling of the majority of protein kinase oncogenes known to date.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Receptor tyrosine kinases (RTKs) form multiprotein complexes at the cell membrane that mediate signal initiation and propagation, as well as feedback control mechanisms (<xref ref-type="bibr" rid="bib25">Lemmon and Schlessinger, 2010</xref>). While cell-free activity profiling may only uncover chemicals that directly target RTK catalytic function, in-cell profiling confers several additional benefits that could improve the drug development process. First, RTKs are targeted in their natural conformation, with post-translational modifications and in theÂ cell metabolic environment. The protein-protein interactions involved in signal transduction through the RTK-associated signaling complexes, downstream elements, or effector pathways may also be targeted, increasing the chance of success. In-cell profiling may identify biological pathways that naturally oppose the signaling of a certain RTK, and can then be therapeutically exploited (<xref ref-type="bibr" rid="bib38">Wendt et al., 2015</xref>). Furthermore, this approach may also enable the targeting of RTKs in non-signaling states, via interference either with their expression, maturation and transport to the cell membrane or their internalization and degradation. Finally, in-cell activity profiling is applicable to disease-specific in vitro and in vivo models. This is important in the development of therapeutics for chronic diseases caused by pathological RTK signaling, such as diabetes, pulmonary hypertension, chronic kidney disease, or developmental disorders (<xref ref-type="bibr" rid="bib11">Fountas et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">ten Freyhaus et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Harskamp et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Laederich and Horton, 2012</xref>), all of which are poorly represented in current clinic (<xref ref-type="bibr" rid="bib2">Bamborough, 2012</xref>). Lastly, several important oncogenes and downstream targets of RTK signaling, such as RAS, appear not druggable directly (<xref ref-type="bibr" rid="bib6">Cox et al., 2014</xref>) and thus the inhibitors of their signaling may only be discovered via in-cell activity profiling. However, the existing toolkits for in-cell RTK activity profiling provide only partial solutions for the development of RTK inhibitors, as they only focus on a few RTKs or their disease-associated mutants (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1A</xref>), are technically or instrumentally challenging, or require the development of RTK-specific tools (<xref ref-type="bibr" rid="bib30">Ni et al., 2006</xref>; <xref ref-type="bibr" rid="bib16">InglÃ©s-Prieto et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Regot et al., 2014</xref>).</p><p>A majority of known RTKs activate the RAS/RAF/MEK/ERK MAP kinase signaling module, a pathway that links extracellular mitogenic signals to gene transcription (<xref ref-type="bibr" rid="bib36">Vogelstein et al., 2013</xref>; <xref ref-type="bibr" rid="bib27">Meloche and PouyssÃ©gur, 2007</xref>). Hence, the strong effect of ERK on gene transcription could be exploited in the development of reporters that are applicable to the activity profiling of many different RTKs (<xref ref-type="bibr" rid="bib39">Yang et al., 2003</xref>). Here, we report the engineering of one such system, which is based on the promoter sequences of the ERK target gene <italic>EGR1</italic> (<italic>Early growth response 1</italic>). We demonstrate that the <italic>EGR1</italic>-based reporter system is applicable to simple in-cell activity profiling of most protein kinase oncogenes. Additionally, we generate proof-of-concept examples for the use of this system in the identification of novel targets for clinically used protein kinase inhibitors.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><sec id="s2-1"><title>Exploitation of the <italic>EGR1</italic> for the activity profiling of fibroblast growth factor receptor (FGFR)</title><p>We focused on the particularly strong ERK activation triggered by FGFR signaling in multiple myeloma and <underline>r</underline>at <underline>c</underline>hondro<underline>s</underline>arcoma (RCS) cells to identify genes which are upregulated upon ERK activation. The expression profiling of cells treated with FGFR ligand FGF2 identified <italic>Egr1</italic>, <italic>Egr2</italic>, <italic>Nr4A2</italic>, <italic>Dusp6</italic> and <italic>Rgs1</italic> among the most strongly induced genes (<xref ref-type="bibr" rid="bib19">Krejci et al., 2010</xref>; <xref ref-type="bibr" rid="bib3">Buchtova et al., 2015</xref>). The putative promoter sequences of human <italic>EGR1</italic>, <italic>EGR2</italic>, <italic>NR4A2</italic>, <italic>DUSP6</italic> and <italic>RGS1,</italic> located directly upstream of the transcription start sites (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1B</xref>), were cloned into the promoterless pGL4.17 vector carrying firefly luciferase. In dual-luciferase activity assays performed in RCS cells, <italic>EGR1</italic> promoter showed the strongest response, as it was <italic>trans</italic>-activated approximately 12-fold following FGF2 treatment (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), and was therefore chosen for subsequent studies. FGF2 induced endogenous EGR1 protein expression in seven different cell types tested, and this phenotype was dependent on ERK activation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.21536.002</object-id><label>Figure 1.</label><caption><title>DevelopmentÂ ofÂ luciferase and fluorescent reporters based on a human <italic>EGR1</italic> promoter.</title><p>(<bold>A</bold>) The activity of various reporters, based on promoters of FGF2-responsive genes, cloned into a pGL4.17 vector expressing firefly luciferase. The FGF2-mediated <italic>trans</italic>-activation (fold-change compared to unstimulated cells) of these reporters in RCS cells was determined by the dual-luciferase assay. Insert, induction of EGR1 protein expression in RCS cells treated with FGF2. (<bold>B</bold>â<bold>E</bold>) Four consecutive rounds of <italic>EGR1</italic> promoter sequence optimization leading to the pKrox24(2xD-E_inD)<sup>Luc</sup> reporter, including 5â-prime shortening (<bold>B</bold>,<bold>C</bold>), 3â-prime shortening (<bold>D</bold>), and addition of repetitive D-elements (<bold>E</bold>) to the originally cloned <italic>EGR1</italic> promoter (vectors outlined in <xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2</xref>). The presented data were generated through dual-luciferase assays in RCS cells, with ânâ describing the number of independent experiments. Statistically significant differences are highlighted (StudentÂ´s t-test; **p&lt;0.01, ***p&lt;0.001). (<bold>F</bold>, <bold>G</bold>) FGF2-mediated induction of dTomato protein expression (<bold>F</bold>) and fluorescence (<bold>G</bold>) in RCS cells transiently transfected with pKrox24(2xD-E)<sup>dTomato</sup> or pKrox24(MapErk)<sup>dTomato</sup> reporters. Bar, 150 Âµm. (<bold>H</bold>) Transactivation of pKrox24(2xD-E)<sup>dTomato</sup> in RCS cells induced by forced expression of the constitutively active FGFR3 K650M mutant, determined by live cell imaging of dTomato fluorescence over 24 hr. The dTomato induction was suppressed by the FGFR inhibitor AZD1480. (<bold>I</bold>) Immunoblot validation of DsRed induction and ERK phosphorylation (p) in RCS cells transfected with FGFR3 K650M mutant together with pKrox24(2xD-E)<sup>DsRed</sup> for 16 hr. Actin and total ERK levels served as loading controls.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.002">http://dx.doi.org/10.7554/eLife.21536.002</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig1-v1"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.003</object-id><label>Figure 1âfigure supplement 1.</label><caption><title>FGF2 induces EGR1 expression dependent on ERK MAP kinase.</title><p>(<bold>A</bold>) Immunoblot analysis of EGR1 protein induction in cultured cells treated with FGFR ligand FGF2 (40 ng/ml in hESC, hiPSC and NIH3T3; 10 ng/mlÂ +1 Âµg/ml heparin in 293T, LP1 and KMS11 cells) for indicated times. hESC, human embryonic stem cells; hiPSC, human induced pluripotent stem cells; NIH3T3, mouse embryonal fibroblasts; 293T, human embryonal kidney cells; LP1, KMS11 human multiple myeloma cell lines. Actin serves asÂ the loading control. (<bold>B</bold>) RCS cells were treated with ERK MAP kinase pathway inhibitor PD0325901 for 30 min prior FGF2 addition, and analyzed for ERK activating phosphorylation (pERK) and EGR1 induction one hour later. EGR1 induction by FGF2 depends on ERK activity. Actin and total ERK levels serve as loading controls. Data show representative experiment for three independent experiments.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.003">http://dx.doi.org/10.7554/eLife.21536.003</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig1-figsupp1-v1"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.004</object-id><label>Figure 1âfigure supplement 2.</label><caption><title>Schematic outline of human <italic>EGR1</italic> promoter sequences cloned into the promoterless pGL4.17 vector carrying firefly luciferase, and analyzed for FGF2-mediated <italic>trans</italic>-activation as shown by <xref ref-type="fig" rid="fig1">Figure 1AâE</xref>.</title><p>The variants generated during four rounds of experimental optimization are indicated. TSS, transcription start site.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.004">http://dx.doi.org/10.7554/eLife.21536.004</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig1-figsupp2-v1"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.005</object-id><label>Figure 1âfigure supplement 3.</label><caption><title>Analysis workflow of the dual-luciferase assay.</title><p>Cells were transfected with promoterless pGL4.17 vector expressing firefly luciferase or containing cloned <italic>EGR1</italic> promoter (pGL4.17-EGR1-D), together with vector carrying <italic>Renilla</italic> luciferase under constant promoter (pRL-TK) (transfection control).Â Chemiluminescence signals generated by each luciferase were determined by dual-luciferase assay (left graph; nÂ =Â 8, four biological replicates each measured twice) and used to calculate F-luc/<italic>R</italic>-luc ratios for control and FGF2-treated cells (middle graph). These ratios were used to calculate a fold difference in pGL4.17-EGR1-D <italic>trans</italic>-activation between untreated and FGF2-stimulated cells (right graph).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.005">http://dx.doi.org/10.7554/eLife.21536.005</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig1-figsupp3-v1"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.006</object-id><label>Figure 1âfigure supplement 4.</label><caption><title>The extent of pKrox24(2xD-E_inD)<sup>Luc</sup> reporter <italic>trans</italic>-activation with increasing FGF2 concentrations in RCS cells.</title><p>Data are generated by dual-luciferase assay and represent an average from indicated number of independent experiments (n) with SEM.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.006">http://dx.doi.org/10.7554/eLife.21536.006</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig1-figsupp4-v1"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.007</object-id><label>Figure 1âfigure supplement 5.</label><caption><title>Validation of pKrox24(2xD-E_inD)<sup>Luc</sup> reporter in cellular models to FGFR signaling.</title><p>(<bold>A</bold>) Cultured 293T and NIH3T3 cells were transfected with pKrox24(2xD-E_inD)<sup>Luc</sup>, treated with FGF2 24 hr later and analyzed by luciferase assay after 20 hr. FGF2 <italic>trans</italic>-activated pKrox24(2xD-E_inD)<sup>Luc</sup> in both cell types. (<bold>B</bold>) hESC, hiPSC and KMS11 cells were transfected similar to (<bold>A</bold>) and endogenous high levels of FGF signaling were inhibited by small chemical inhibitors of FGFR catalytic activity AZD1480 (2 ÂµM) and BGJ398 (10, 20, 40, 100 nM). Statistically significant differences are indicated (StudentÂ´s t-test; *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). n, number of independent experiments.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.007">http://dx.doi.org/10.7554/eLife.21536.007</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig1-figsupp5-v1"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.008</object-id><label>Figure 1âfigure supplement 6.</label><caption><title>Generation of pKrox24(MapErk) reporters.</title><p>Conserved transcription factor binding sites were mapped to human <italic>EGR1</italic> promoter together with information obtained during development of pKrox24(2xD-E_inD) reporters. A region crucial for theÂ activity of the reporter overlapped with evolutionary conserved element (yellow box) and thus it was analyzed for transcription factors binding sites. Selected transcription factor responsive elements were then used for construction of the synthetic reporter where binding sites (BS) for SP1, CREB1, ELK1, ELK4, SRF and EGR1 itself were cloned five times in a row into pGL4.26 vector. TSS, transcription start site.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.008">http://dx.doi.org/10.7554/eLife.21536.008</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig1-figsupp6-v1"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.009</object-id><label>Figure 1âfigure supplement 7.</label><caption><title>Comparison of transactivation capacity and basal activity of pKrox24(MapErk)and pKrox24(2xD-E_inD) reporters.</title><p>(<bold>A</bold>) Comparison of FGF2-mediated <italic>trans</italic>-activation pKrox24(2xD-E_inD)<sup>Luc</sup>, pKrox24(MapErk)<sup>Luc</sup> and pGL4.17-EGR1-D reporters in RCS cells. Statistically significant differences are indicated (StudentÂ´s t-test; *p&lt;0.05, **p&lt;0.01). (<bold>B</bold>) Determination of basal levels of pKrox24(2xD-E_inD)<sup>Luc</sup> and pKrox24(MapErk)<sup>Luc</sup> activity in untreated 293T and RCS cells, transfected with indicated vectors for 24 hr, parental vectors are also shown. Data generated by dual-luciferase assay. n, number of independent experiments.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.009">http://dx.doi.org/10.7554/eLife.21536.009</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig1-figsupp7-v1"/></fig><fig id="fig1s8" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.010</object-id><label>Figure 1âfigure supplement 8.</label><caption><title>FGF-mediated transactivation of constructs containing D-E or MapErk promoter elements combined with dTomato or DsRed reporters.</title><p>(<bold>A</bold>) RCS cells were transfected with pCLuc-Basic2 vector expressing dTomato under the pKrox24(2xD-E) promoter and treated with FGF2 (50 ng/ml) for 24 hr. dTomato expression was monitored by automatic incubation microscope BioStation CT (Nikon) over the entire 24 hr period of time and plotted (<bold>B</bold>) against signal recorded in FGF2-naÃ¯ve cells transfected with pKrox24(2xD-E)<sup>dTomato</sup>. Scale bar 150 Âµm. (<bold>C</bold>) RCS cells were transiently transfected with activating FGFR3 mutant K650M together with pKrox24(2xD-E)<sup>dTomato</sup> vector for 24 hr alone or in the presence of FGFR inhibitor AZD1480. Representative images at 24 hr were acquired using confocal microscope Carl Zeiss LSM 700. Bar, 150 Âµm. dTomato fluorescence was recorded by BioStation CT over the entire 24 hr period of time, data are graphed and presented at <xref ref-type="fig" rid="fig1">Figure 1H</xref>. (<bold>D</bold>) Immunoblot analysis of dTomato and DsRed induction in FGF2-treated RCS cells transfected with vectors expressing DsRed and dTomato under the control of both pKrox24(2xD-E) and pKrox24(MapErk) promoters. Controls are non-transfected cells or those transfected with empty plasmid. Actin serves as theÂ loading control. Numbers of independent experiments (n): 4 (<bold>A</bold>), 4 (<bold>B</bold>), 3 (<bold>C</bold>), 3 (<bold>D</bold>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.010">http://dx.doi.org/10.7554/eLife.21536.010</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig1-figsupp8-v1"/></fig></fig-group></p><p>To identify FGF2-responsive elements, we generated 13 truncated variants of the 2112nt-long human <italic>EGR1</italic> promoter that had originally been cloned into the pGL4.17 vector (â1951/+161 relative to the transcription start site; TSS) (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2</xref>), and subjected these variants to FGF2-mediated <italic>trans</italic>-activation in a dual-luciferase assay (<xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3</xref>). Four successive rounds of 3- and/or 5-prime sequence shortening and optimization identified a 402nt-long region (â799/â397 relative to TSS) that is critical for FGF2-mediated <italic>trans</italic>-activation (called D-E element) of the <italic>EGR1</italic> promoter (<xref ref-type="fig" rid="fig1">Figure 1BâD</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2</xref>). The addition of two extra copies of the D-E element into the <italic>EGR1</italic> promoter (hEGR1-D) enhanced its response to FGF2 by approximately 50% (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). We named this construct pKrox24(2xD-E_inD)<sup>Luc</sup> after KROX24, one of the alternative names of EGR1 (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1C</xref>). The level of pKrox24(2xD-E_inD)<sup>Luc</sup> FGF2-mediated <italic>trans</italic>-activation in RCS cells peaked at approximately 40 ng/ml FGF2. Treatment of RCS cells with higher doses of FGF2 further elevated ERK activation (<xref ref-type="bibr" rid="bib20">Krejci et al., 2007</xref>), but had a negligible effect on pKrox24(2xD-E_inD)<sup>Luc</sup> activity (<xref ref-type="fig" rid="fig1s4">Figure 1âfigure supplement 4</xref>), implying that it is unlikely that further development of the pKrox24(2xD-E_inD)<sup>Luc</sup> promoter sequence would yield a significant increase in trans-activation capacity. In the five different cell types tested, pKrox24(2xD-E_inD)<sup>Luc</sup> responded to the activation of FGFR signaling following FGF2 addition, as well as to the chemical inhibition of endogenous FGFR signaling (<xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref>).</p><p>To eliminate inhibitory elements possibly existing within the pKrox24(2xD-E_inD)<sup>Luc</sup> promoter, a fully synthetic construct was developed, based on <italic>EGR1</italic> promoter and information gained during the pKrox24 development. A human <italic>EGR1</italic> promoter sequence (â1500/+100 bp relative to TSS) was aligned with the corresponding sequences of pig, cow, rat, mouse and chicken <italic>Egr1</italic>, and analyzed by T-Coffee (<xref ref-type="bibr" rid="bib31">Notredame et al., 2000</xref>) to find conserved elements, and by rVista (<xref ref-type="bibr" rid="bib26">Loots and Ovcharenko, 2004</xref>) to identify transcription factor binding sites. The identified elements, together with previously discovered sequences (<xref ref-type="bibr" rid="bib37">Wang et al., 2010</xref>), were mapped onto the <italic>EGR1</italic> promoter and cloned into a pGL4.26 vector containing a minimal promoter and firefly luciferase. The resulting reporter was named pKrox24(MapErk)<sup>Luc</sup> (<xref ref-type="fig" rid="fig1s6">Figure 1âfigure supplement 6</xref>). When compared to pKrox24(2xD-E_inD)<sup>Luc</sup>, pKrox24(MapErk)<sup>Luc</sup> showed no additional increase in FGF2-mediated <italic>trans</italic>-activation, but possessed a significantly lower basal activity in RCS and 293T cells (<xref ref-type="fig" rid="fig1s7">Figure 1âfigure supplement 7</xref>).</p><p>Additionally, constructs containing five copies of MapErk or two copies of D-E elements, serving as minimal promoters, were generated with either dTomato or DsRed reporter (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1C</xref>). These reporters responded well to FGF2-mediated <italic>trans</italic>-activation following transfection into RCS cells, shown by immunoblot analyses of dTomato and DsRed expression, and live cell imaging (<xref ref-type="fig" rid="fig1">Figure 1F,G</xref>; <xref ref-type="fig" rid="fig1s8">Figure 1âfigure supplement 8</xref>). Expression of the constitutively active FGFR3 mutant K650M (<xref ref-type="bibr" rid="bib29">Naski et al., 1996</xref>) in RCS cells induced dTomato or DsRed expression, and this expression was reversed by treatment with AZD1480, a chemical inhibitor of FGFR3 (<xref ref-type="bibr" rid="bib34">Scuto et al., 2011</xref>) (<xref ref-type="fig" rid="fig1">Figure 1H,I</xref>; <xref ref-type="fig" rid="fig1s8">Figure 1âfigure supplement 8C</xref>).</p></sec><sec id="s2-2"><title>Protein kinases induce EGR1 protein expression in cells</title><p>Next, we investigated whether RTKs other than FGFRs induce EGR1 expression in cells. A total of 37 full-length human wild-type (wt) RTKs were cloned into the pcDNA3.1 vector in frame with a C-terminal V5/6xHis epitope, expressed in 293T cells, and verified by immunoblot (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>). Site-directed mutagenesis was used to generate the major mutants of each RTK associated with human disease, obtained via surveys of published literature, or selected from the catalogue of mutations associated with human cancers or inherited conditions available from the Sanger Cosmic (<xref ref-type="bibr" rid="bib10">Forbes et al., 2015</xref>) and OMIM databases. As RTKs auto-phosphorylate upon activation (<xref ref-type="bibr" rid="bib1">Bae and Schlessinger, 2010</xref>), a phosphorylation-specific RTK antibodies were used to estimate the spontaneous or ligand-induced activation of expressed RTKs (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>; <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1D</xref>). A total of 254 wt and mutant RTK variants were prepared this way, expressed in 293T cells, and analyzed for EGR1 induction. The results showed that 30 wt RTKs (81%) and 154 (71%) of their mutants induced EGR1 when expressed in 293T cells (<xref ref-type="fig" rid="fig4">Figure 4</xref>).<fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.21536.011</object-id><label>Figure 2.</label><caption><title>RTK cloning and validation (part 1).</title><p>Full-length human RTK cDNA was cloned into pcDNA3.1 vectors and equipped with a C-terminal V5/His epitope. Mutants were created by site-directed mutagenesis. The RTKs were expressed in 293T cells, and their activation was probed by immunoblot with antibodies that recognize the given RTK only when it is phosphorylated (p) at a specific motif, with exception of phosphorylated DDR1 and DDR2 which were detected with pan-pY antibody. A total of 37 wild-type (WT) RTKs and 241 of their mutants were obtained, including disease-associated loss-of-function and gain-of-function mutants, and experimental kinase-inactive mutants (KD). Treatment with the cognate ligands of DDR1, DDR2, KIT, and VEGFR2 was used for the activation of these RTKs.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.011">http://dx.doi.org/10.7554/eLife.21536.011</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig2-v1"/></fig><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.21536.012</object-id><label>Figure 3.</label><caption><title>RTK cloning and validation (part 2).</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.012">http://dx.doi.org/10.7554/eLife.21536.012</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig3-v1"/></fig></p><p>Three wt RTKs (FGFR3, TIE, VEGFR1) and 27 mutants induced EGR1 expression but were not found to be phosphorylated (<xref ref-type="fig" rid="fig2">Figures 2</xref>â<xref ref-type="fig" rid="fig4">4</xref>). This is likely due to the fact that in active RTKs some phosphotyrosines are differentially phosphorylated and thus may not be identified by antibodies designed for specific motifs. The most notable example is FGFR3, as all five active mutants associated with skeletal dysplasia and cancer (<xref ref-type="bibr" rid="bib18">Kant et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Passos-Bueno et al., 1999</xref>; <xref ref-type="bibr" rid="bib4">Carter et al., 2015</xref>) induced EGR1, but only K650M FGFR3 was found to be phosphorylated by an antibody recognizing FGFR phosphorylation at Y653/Y654. The pseudokinases lacking catalytic activity (ROR1, ROR2, RYK, ERBB3) were among the RTKs that did not induce EGR1, along with RTKs that did not autophosphorylate after expression in 293T cells (TYRO3, INSRR, ROS1) (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>). Furthermore, 36 mutants failed to induce EGR1 despite being derived from RTKs that induce EGR1 expression. The majority of these mutants (83%) were kinase-inactive mutants (<xref ref-type="fig" rid="fig2">Figures 2</xref>â<xref ref-type="fig" rid="fig4">4</xref>). The remaining six mutants did not induce EGR1 because of weak activation (DDR1<sup>R896Q</sup>, ERBB4<sup>E836K</sup>, RET<sup>E768N</sup>) or due to an unknown reason (RON<sup>R470C</sup>, RON<sup>R1231C</sup>, PDGFRB<sup>D850N</sup>). Overall, the RTK activation correlated with EGR1 induction in 96% (154 out of 160) of the tested wt and mutant RTKs. Thirteen additional non-receptor tyrosine kinases, serine/threonine kinases C-RAF and B-RAF as well as RAS small GTPase, were subjected to the same analyses (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>). Taken together, we have demonstrated that, apart from the JAK and MAPKK kinases not evaluated in this study, all of the protein kinase oncogenes recognized to date (<xref ref-type="bibr" rid="bib36">Vogelstein et al., 2013</xref>) are capable of inducing EGR1 expression in 293T cells.<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.21536.013</object-id><label>Figure 4.</label><caption><title>RTKs induce EGR1 protein expression.</title><p>(<bold>A</bold>, <bold>B</bold>) Immunoblot analyses of EGR1 induction in 293T cells transfected with wild-type (WT) or mutated RTKs for 24 hr. Cells transfected with empty plasmids serve as the transfection control, and actin serves as the loading control. (<bold>A</bold>) Green, RTK induces EGR1; red, no EGR1 induction by the RTK; * RTKs that induced EGR1 but were not autophosphorylated (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>); <sup>Â¶</sup> RTKs that were autophosphorylated but did not induce EGR1; <sup>L</sup> RTKs activated by the addition of their cognate ligands.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.013">http://dx.doi.org/10.7554/eLife.21536.013</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig4-v1"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.014</object-id><label>Figure 4âfigure supplement 1.</label><caption><title>EGR1 expression induced by non-receptor tyrosine kinases, serine/threonine kinases C-RAF and B-RAF, and RAS small GTPase.</title><p>(<bold>A</bold>) Immunoblot validation of cytoplasmic tyrosine kinases (ABL, BCR-ABL, ITK, SYK, TEC, TYK2, ZAP70, BLK, FGR, FYN, YES, LCK, LYN), serine/threonine kinases (B-RAF, C-RAF) and small GTPase RAS expression and activation in 293T cells. Cells transfected with empty plasmid serve as transfection control. Actin serves asÂ the loading control. Control, untransfected cells. WT, wild-type RAS, V12, active RAS mutant. Two variants (p190 and p210) of oncogenic BCR-ABL are shown. CAAX, active C-RAF variant; V600E, oncogenic B-RAF mutant. (<bold>B</bold>) Immunoblot analysis of EGR1 protein induction in 293T cells, following 24 hr of expression of theÂ indicated proteins in 293T cells. (<bold>C</bold>) Compilation of the data generated in (<bold>B</bold>). Green, expression of given protein induces EGR1; red, no EGR1 protein induction; * kinases that induced EGR1 but were not found autophosphorylated; <sup>Â¶</sup> kinases which did not induce EGR1 but were found autophosphorylated. Data show aÂ representative experiment for three independent experiments.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.014">http://dx.doi.org/10.7554/eLife.21536.014</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig4-figsupp1-v1"/></fig></fig-group></p></sec><sec id="s2-3"><title>pKrox24 reporters can be used to identify novel targets for clinically used kinase inhibitors</title><p>One application of pKrox24 reporters is the identification of novel targets for clinically used kinase inhibitors, which could help repurpose existing anti-cancer drugs or uncover the molecular mechanisms underlying the side-effects they cause in patients. Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by a t(9;22)(q34;q11) translocation that produces a cytoplasmic BCR-ABL fusion protein with constitutive tyrosine kinase activity (<xref ref-type="bibr" rid="bib42">Zhao et al., 2002</xref>). The suppression of BCR-ABL catalytic activity with tyrosine kinase inhibitors (TKI) has greatly improved CML prognosis, effectively turning a once fatal cancer into a manageable chronic disease. Several generations of BCR-ABL TKIs have been developed to improve efficacy and overcome the BCR-ABL resistance to first generation TKIs caused by mutations and gene amplifications (<xref ref-type="bibr" rid="bib14">Hochhaus et al., 2008</xref>; <xref ref-type="bibr" rid="bib5">Cortes et al., 2013</xref>). However, some TKIs, such as ponatinib, can cause severe toxicity in CML patients and even lead to discontinuation of the therapy (<xref ref-type="bibr" rid="bib28">Modugno, 2014</xref>). The reasons why these BCR-ABL TKI side-effects occur are not clear, and in this way, the elucidation of how TKIs affect physiological tyrosine kinase signaling is of major interest to CML research. To identify novel targets, we evaluated the activity of five clinically used BCR-ABL TKIs, thatÂ is ponatinib, imatinib, dasatinib, bosutinib and nilotinib, against a panel of 28 wt RTKs. Different TKI concentrations were used to assess the inhibition of BCR-ABL activity as well as cell toxicity (<xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1A</xref>). <xref ref-type="fig" rid="fig5">Figure 5A</xref> shows that all tested TKIs inhibited RTKs that had already been reported as targets in literature (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1E</xref>), with exception of LTK and INSR, which were identified as two novel targets for nilotinib (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1E</xref>).<fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.21536.015</object-id><label>Figure 5.</label><caption><title>In-cell RTK activity profiling with BCR-ABL and EGFR inhibitors.</title><p>(<bold>A</bold>) Activity of BCR-ABL inhibitors ponatinib (<italic>Pona.</italic>), imatinib (<italic>Ima.</italic>), dasatinib (<italic>Dasa.</italic>), bosutinib (<italic>Bosu.</italic>), and nilotinib (<italic>Nilo.</italic>) against 28 wild-type RTKs, evaluated in 293T cells transfected with RTKs and treated with inhibitors for 20â24 hr. The panel compiles data from immunoblot detections of activated RTKs, each treated with inhibitor concentrations derived from the experiments shown in <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>. Only one concentration is shown for nilotinib due to its cell toxicity at higher concentrations. Asterisks highlight the previously unreported nilotinib targets LTK and INSR (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1E</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>). (<bold>B</bold>) Activity profiling of 30 wild-type (wt) RTKs and 116 of their active mutants in the presence of 0.5 ÂµM osimertinib. 293T cells were transfected with RTK vectors together with pKrox24(2xD-E_inD)<sup>Luc</sup>24 hr before osimertinib treatment (for 24 hr). The colors reflect the osimertinib-mediated inhibition of pKrox24(2xD-E_inD)<sup>Luc</sup><italic>trans</italic>-activation induced by a given RTK, relative to cells untreated with osimertinib. Basal levels of osimetrinib-mediated inhibition of pKrox24(2xD-E_inD)<sup>Luc</sup> were obtained from cells transfected with empty plasmid and then subtracted from the data. (<bold>C</bold>) 293T cells were transfected with wt LTK or its mutants, and treated with osimertinib (Osi.) for 24 hr. The LTK autophosphorylation (p) reflect LTK activity. Total LTK and actin serve as loading controls. (<bold>D</bold>) Cell-free kinase assays were carried out with recombinant LTK or EGFR and osimertinib added to the kinase reaction. Phosphorylation (p) of a recombinant STAT1 and autophosphorylation was used to detect LTK and EGFR activation, respectively. Samples with omitted ATP serve as negative controls for kinase activity.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.015">http://dx.doi.org/10.7554/eLife.21536.015</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig5-v1"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.21536.016</object-id><label>Figure 5âfigure supplement 1.</label><caption><title>Analyses of cytotoxicity and kinase activities of BCR-ABL and EGFR inhibitors.</title><p>(<bold>A</bold>) 293T cells were treated with ponatinib, imatinib, dasatinib, bosutinib, nilotinib and osimertinib for 24 hr and the cell amounts were determined by cell counting. Data represent average from three independent experiments (two biological replicates for each point in every experiment) with indicated SD. 0, cells treated with TKI vehicle DMSO. With exception of dasatinib, the inhibitors did not affect 293T proliferation at the concentration ranges (red lines) used in RTK screening (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). (<bold>B</bold>, <bold>C</bold>) Cells were transfected with human wild-type ABL, and p190 and p210 variants of BCR-ABL, and wild-type human EGFR or its activating mutant T790M, treated with inhibitors for 24 hr and analyzed for activating phosphorylation (p) by immunoblot. Actin and total levels of expressed kinases serve as loading controls. Cells transfected with empty plasmid serve as transfection control. (<bold>D</bold>) Evidence demonstrating that 2 and 5 Î¼M nilotinib inhibits expression of transfected FGFR2, MET and RON. (<bold>E</bold>) Inhibition of LTK and INSR autophosphorylation by nilotinib. (<bold>B</bold>â<bold>E</bold>) Data show aÂ representative experiment for three independent experiments.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.016">http://dx.doi.org/10.7554/eLife.21536.016</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-fig5-figsupp1-v1"/></fig></fig-group></p><p>Osimertinib (AZD9291) is recently described inhibitor of EGFR catalytic activity, and was approved for clinical use in lung carcinoma in 2015 (<xref ref-type="bibr" rid="bib7">Cross et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Greig and Approval, 2016</xref>). Osimertinib is a mutant-selective EGFR inhibitor, with 200-fold selectivity for EGFR mutants T790M and L858R over the wt EGFR (<xref ref-type="bibr" rid="bib7">Cross et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Finlay et al., 2014</xref>; <xref ref-type="bibr" rid="bib17">Jiang and Zhou, 2014</xref>). Crystallographic studies indicate that osimertinib binds to the outer edge of the EGFR ATP binding pocket through a covalent bond with Cys797 (<xref ref-type="bibr" rid="bib41">Yosaatmadja et al., 2015</xref>). Although these data provide no clear explanation for EGFR mutant versus the wt selectivity (<xref ref-type="bibr" rid="bib7">Cross et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Finlay et al., 2014</xref>; <xref ref-type="bibr" rid="bib17">Jiang and Zhou, 2014</xref>; <xref ref-type="bibr" rid="bib41">Yosaatmadja et al., 2015</xref>), osimertinib is expected to possess a very narrow spectrum of RTK specificity, limited to EGFR and the closely related ERBB2 and ERBB4. We tested this prediction by evaluating osimertinib activity against 30 wt RTKs and 116 of their active mutants with a pKrox24(2xD-E_inD)<sup>Luc</sup> luciferase assay in 293T cells. We observed inhibitory activity for osimertinib against EGFR, ERBB2 and ERBB4, but not for the other 26 RTKs and 99 mutants (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). However, LTK was an exception, as it appeared to be inhibited by osimertinib in both wt and mutant forms. These included the D535N and L844I mutants, which associate with multiple myeloma and stomach carcinoma (<xref ref-type="bibr" rid="bib15">Hucthagowder et al., 2012</xref>; <xref ref-type="bibr" rid="bib22">Kubo et al., 2009</xref>), respectively, and the W831C and H608Y substitutions found in the Cosmic and VarSome databases. The osimertinib activity was confirmed by suppression of the autophosphorylation of LTK expressed in 293T cells, and by inhibition of LTK-mediated phosphorylation of recombinant STAT1 substrate in cell-free kinase assays (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><p>The presented pKrox24 technology enables rapid in-cell profiling of a majority of the known protein kinase oncogenes via simple and versatile reporters based on the activity of a downstream protein kinase signaling target. While the luciferase reporters may be applied to tractable cell models to repurpose existing protein kinase inhibitors, the application of fluorescent pKrox24 reporters to high-throughput screening (HTS) of compound libraries offers a major advantage. Cells can be viewed any time during the screening, and this characteristic of HTS would enable researchers to detect false-positive hits based on the inhibition of dTomato and DsRed expression by cell-toxic compounds through mechanisms unrelated to the target protein kinase. Hence, these reporters could improve the interpretation of HTS screening data by readily eliminating false-positive hits.</p></sec></sec><sec id="s3" sec-type="methods"><title>Methods</title><sec id="s3-1"><title>Cell culture, transfection and luciferase reporter assay</title><p>NIH3T3 cells (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0594">CVCL_0594</ext-link>) and 293 T cells (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0063">CVCL_0063</ext-link>) were obtained from ATCC (Manassas, VA). hiPSC cell line AM13 was generated as described before (<xref ref-type="bibr" rid="bib21">KrutÃ¡ et al., 2014</xref>). hESC (CCTL14; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_C860">CVCL_C860</ext-link>) cells were prepared as described before (<xref ref-type="bibr" rid="bib8">Dvorak et al., 2005</xref>). RCS cells (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_S122">CVCL_S122</ext-link>), KMS11 (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_2989">CVCL_2989</ext-link>) and LP1 (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0012">CVCL_0012</ext-link>) cells were obtained as described before (<xref ref-type="bibr" rid="bib19">Krejci et al., 2010</xref>). All used cell lines were routinely evaluated for mycoplasma contamination using DAPI staining and confocal microscopy, and were mycoplasma free. Cells were propagated in DMEM media, supplemented with 10% FBS and antibiotics (Invitrogen, Carlsbad, CA). hESC and hiPSC cells were propagated in feeder-free conditions. For 293T growth assays, 3 Ã 10 cells were grown in 24-well tissue culture plates for 1 day, and the cells were treated with inhibitors. After 24 hr the cell numbers were determined by cell counter (Beckman Coulter, Brea, CA). Chemicals were obtained from the following manufacturers: FGF2, SCF, FLT3 ligand, VEGF (RnD Systems, Minneapolis, MN); collagen type 1 (Santa Cruz Biotechnology, Santa Cruz, CA); PD0325901 (Tocris Bioscience, Bristol, UK); ponatinib, imatinib, dasatinib, bosutinib, nilotinib, osimertinib, AZD1480, BGJ398 (Selleckchem, Houston, TX); heparin (Sigma-Aldrich, St. Louis, MO). Cells were transfected either by using FuGENE6 transfection reagent (Roche, Basel, Switzerland), polyethylenimine (Sigma-Aldrich) or electroporation with the Neon Transfection System (Invitrogen). For the luciferase reporter assay, cells were also transfected with a vector expressing firefly luciferase and a vector expressing <italic>Renilla</italic> luciferase under the control of a constant promoter (pRL-TK) at a 3/1 ratio. Luciferase signal was quantified 20â24 hr later using the Luciferase or Dual-Luciferase Reporter Assay (Promega, Madison, WI). Osimertinib screening in 293T cells was carried out with pKrox24(2xD-E)<sup>Luc</sup>only, which was transfected at a 1/3 ratio together with the RTK-expressing vector. The cells were treated with 0.5 ÂµM osimertinib 24 hr after transfection, and luciferase signal was determined 24 hr later.</p></sec><sec id="s3-2"><title>Plasmid cloning and mutagenesis</title><p>Vectors (pcDNA3.1) carrying C-terminally V5-tagged RTKs were generated by cloning full-length human RTK cDNA into a pcDNA3.1/V5-His TOPO TA vector (Invitrogen). Site-directed mutagenesis was carried-out according to the manufacturerâs protocol (Agilent, Santa Clara, CA). Vectors (pCR3.1) carrying N-terminally FLAG-tagged p190 and p210 variants of BCR-ABL were generated by cloning full-length human BCR-ABL p190 cDNA (source pSG5-P190) and full-length human BCR-ABL p210 cDNA (source Bcr/Abl P210LEF) into a pCR3.1 vector (Invitrogen) containing a PGNQNMDYKDDDDK amino acid coding sequence between BamHI and EcoRI in the multiple cloning site. The source vectors pSG5-P190 (Addgene, Cambridge, MA; plasmid #31285) and Bcr/Abl P210LEF (plasmid #38158) were a gift from Nora Heisterkamp (<xref ref-type="bibr" rid="bib40">Yi et al., 2008</xref>; <xref ref-type="bibr" rid="bib23">Kweon et al., 2008</xref>). Promoter regions of <italic>EGR1</italic>, <italic>EGR2</italic>, <italic>RGS1</italic>, <italic>NR4A2</italic> and <italic>DUSP6</italic> were amplified from hESC genomic DNA by PCR and ligated to a pGL4.17 vector (Promega). All EGR1 promoter fragments of different lengths (hEGR1-B - hEGR1-F) were amplified from hEGR1-A by PCR and inserted into vector pGL4.17. The construct pKrox24(1xD-E_inD)<sup>Luc</sup> was prepared by inserting the active element D-E, amplified from hEGR1-A by PCR, into the hEGR1-D construct. pKrox24(2xD-E_inD)<sup>Luc</sup> was obtained by cloning synthetic DNA corresponding to two copies of the active element D-E to KpnI site of the hEGR1-D construct. pKrox24(3xD-D2_inD)<sup>Luc</sup> was obtained by cloning three copies of the active element D-D2 as a synthetic gene by KpnI into the hEGR1-D construct. pKrox24(MapErk)<sup>Luc</sup> was prepared by inserting synthetic DNA corresponding to five copies of a designed MapErk sequence (listed in <xref ref-type="fig" rid="fig1s6">Figure 1âfigure supplement 6</xref>) into KpnI, HindIII sites of the pGL4.26 vector (Promega). Two copies of synthetic DNA corresponding to element D-E were cloned into HindIII,SalI sites of pDsRed-Express-DrVector (Clontech) to obtain pKrox24(2xD-E)<sup>DsRed</sup>. pKrox24(MapErk)<sup>DsRed</sup> was prepared by cloning of five copies of designed MapErk sequence into EcoRI,BamHI sites of the pDsRed-Express-Dr vector. pKrox24(2xD-E)<sup>dTomato</sup> and pKrox24(MapErk)<sup>dTomato</sup> were generated by swapping of dTomato cDNA from ptdTomato Vector (Clontech) to pCLuc-Basic2 by HindIII,NotI and BamHI,NotI sites, respectively. 2xD-E element was cloned to pCLuc-Basic2 by EcoRI,EcoRV sites, MapErk element was cloned into EcoRI,XhoI sites. <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1C</xref> lists all expression vectors used in the study; <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1F</xref> lists all PCR primers with marked restriction sites used for plasmid generation.</p></sec><sec id="s3-3"><title>Immunoblotting</title><p>Cells were harvested into the sample buffer (125 mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS, 5% Î²-mercaptoethanol, 0.02% bromophenol blue). Samples were resolved by SDS-PAGE, transferred onto a PVDF membrane and visualized by chemiluminiscence (Thermo Scientific, Rockford, IL). <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1D</xref> lists the antibodies used in the study. Kinase assays were performed with 200 ng of recombinant EGFR or LTK (SignalChem, Richmond, CA) in 50 Âµl of kinase buffer (60 mM HEPES pH 7.5, 3 mM MgCl<sub>2</sub>, 3 mM MnCl<sub>2</sub>, 3 ÂµM Na<sub>3</sub>VO<sub>4</sub>, 1.2 mM DTT) in the presence of 10 ÂµM ATP for 60 min at 30Â°C. Recombinant STAT1 was from Cell Science (Newbury port, MA).</p></sec><sec id="s3-4"><title>Live cell imaging</title><p>Time-lapse microscopy experiments with living cells were conducted using either an automated incubation microscope BioStation CT (Nikon, Tokio, Japan) or a confocal laser-scanning microscope Carl Zeiss LSM 700 (Carl Zeiss, Jena, Germany) equipped with an atmospheric chamber. Phase contrast and fluorescence signal images were automatically acquired every 15 min during a 24 hr time period. Images were then processed and analyzed in either Nikon BioStation CT or Carl Zeiss ZEN 2 software. Phase contrast and fluorescence images were exported into Microsoft Publisher for the preparation of publication figures.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors wish to thank Iva Vesela, Iveta Cervenkova, Arelys Puerta and Jorge Martin for their assistance with plasmid cloning, and Miriam Minarikova, Zaneta Konecna and Pavel Nemec for their excellent technical assistance. This work was supported by Ministry of Education, Youth and Sports of the Czech Republic (KONTAKT II LH15231, CZ.1.05/3.1.00/14.0324); Technology Agency of the Czech Republic (TG02010048); Grant Agency of Masaryk University (0071â2013); Czech Science Foundation (GA17â09525S); Ministry of Health of the Czech Republic (15-33232A, 15-34405A); National Program of Sustainability II (MEYS CR: LQ1605 and LQ1601) and European Union ICRC-ERA-HumanBridge (No. 316345); and by funds from the Faculty of Medicine at Masaryk University to junior researcher MKB. SFT received support from the SoMoPro II Programme G4 target, which was co-financed by the European Union and the South-Moravian Region (Note: This publication reflects only the author's views and the Union is not liable for any use that may be made of the information contained therein). LT was supported by the career development grant from the European Organization for Molecular Biology (IG2535) and by the Marie-Curie Re-integration grant (ECOPOD). IG was supported by Specific University Research Grant at Masaryk University (MUNI/A/0810/2016; Ministry of Education, Youth and Sports of the Czech Republic).</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>IG, Conceptualization, Data curation, Formal analysis, Writingâoriginal draft, Writingâreview and editing</p></fn><fn fn-type="con" id="con2"><p>SF-T, Conceptualization, Data curation, Formal analysis, Supervision, Writingâoriginal draft, Writingâreview and editing</p></fn><fn fn-type="con" id="con3"><p>BEG, Data curation</p></fn><fn fn-type="con" id="con4"><p>BF, Conceptualization, Data curation, Formal analysis, Writingâoriginal draft, Writingâreview and editing</p></fn><fn fn-type="con" id="con5"><p>MV, Conceptualization, Data curation, Visualization</p></fn><fn fn-type="con" id="con6"><p>LB, Data curation</p></fn><fn fn-type="con" id="con7"><p>EH, Data curation</p></fn><fn fn-type="con" id="con8"><p>LJ, Data curation</p></fn><fn fn-type="con" id="con9"><p>IJ, Data curation</p></fn><fn fn-type="con" id="con10"><p>MKB, Data curation</p></fn><fn fn-type="con" id="con11"><p>LT, Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Writingâoriginal draft, Writingâreview and editing</p></fn><fn fn-type="con" id="con12"><p>JM, Conceptualization, Resources, Funding acquisition, Writingâoriginal draft, Writingâreview and editing</p></fn><fn fn-type="con" id="con13"><p>PK, Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Writingâoriginal draft, Writingâreview and editing</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.21536.017</object-id><label>Supplementary file 1.</label><caption><title>Supplementary tables containing</title><p>(A) Commercial providers of RTK activity profiling; (B) Nucleotide sequences cloned into the promoterless pGL4.17 vector expressing firefly luciferase; (C) Expression vectors used in the study; (D) Antibodies used in the study; (E) Literature survey of anti-RTK activity of BCR-ABL TKIs; (F) Primers used for reporter construction.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.017">http://dx.doi.org/10.7554/eLife.21536.017</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-21536-supp1-v1.docx"/></supplementary-material><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.21536.018</object-id><label>Supplementary file 2.</label><caption><title>Supplementary file contains numerical data for <xref ref-type="fig" rid="fig1">Figure 1A,B,C,D and E</xref>; <xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplements 3</xref>, <xref ref-type="fig" rid="fig1s4">4</xref>, <xref ref-type="fig" rid="fig1s5">5A, B</xref>, <xref ref-type="fig" rid="fig1s7">7A and B</xref>; and <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.018">http://dx.doi.org/10.7554/eLife.21536.018</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-21536-supp2-v1.xlsx"/></supplementary-material><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.21536.019</object-id><label>Supplementary file 3.</label><caption><title>Supplementary file contains numerical data for <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.019">http://dx.doi.org/10.7554/eLife.21536.019</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-21536-supp3-v1.xlsx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>JH</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases</article-title><source>Molecules and Cells</source><volume>29</volume><fpage>443</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1007/s10059-010-0080-5</pub-id><pub-id pub-id-type="pmid">20432069</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamborough</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>System-based drug discovery within the human kinome</article-title><source>Expert Opinion on Drug Discovery</source><volume>7</volume><fpage>1053</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1517/17460441.2012.724056</pub-id><pub-id pub-id-type="pmid">22971083</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchtova</surname><given-names>M</given-names></name><name><surname>Oralova</surname><given-names>V</given-names></name><name><surname>Aklian</surname><given-names>A</given-names></name><name><surname>Masek</surname><given-names>J</given-names></name><name><surname>Vesela</surname><given-names>I</given-names></name><name><surname>Ouyang</surname><given-names>Z</given-names></name><name><surname>Obadalova</surname><given-names>T</given-names></name><name><surname>Konecna</surname><given-names>Z</given-names></name><name><surname>Spoustova</surname><given-names>T</given-names></name><name><surname>Pospisilova</surname><given-names>T</given-names></name><name><surname>Matula</surname><given-names>P</given-names></name><name><surname>Varecha</surname><given-names>M</given-names></name><name><surname>Balek</surname><given-names>L</given-names></name><name><surname>Gudernova</surname><given-names>I</given-names></name><name><surname>Jelinkova</surname><given-names>I</given-names></name><name><surname>Duran</surname><given-names>I</given-names></name><name><surname>Cervenkova</surname><given-names>I</given-names></name><name><surname>Murakami</surname><given-names>S</given-names></name><name><surname>Kozubik</surname><given-names>A</given-names></name><name><surname>Dvorak</surname><given-names>P</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fibroblast growth factor and canonical WNT/Î²-catenin signaling cooperate in suppression of chondrocyte differentiation in experimental models of FGFR signaling in cartilage</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</source><volume>1852</volume><fpage>839</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2014.12.020</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>EP</given-names></name><name><surname>Fearon</surname><given-names>AE</given-names></name><name><surname>Grose</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction</article-title><source>Trends in Cell Biology</source><volume>25</volume><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2014.11.003</pub-id><pub-id pub-id-type="pmid">25467007</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Pinilla-Ibarz</surname><given-names>J</given-names></name><name><surname>le Coutre</surname><given-names>P</given-names></name><name><surname>Paquette</surname><given-names>R</given-names></name><name><surname>Chuah</surname><given-names>C</given-names></name><name><surname>Nicolini</surname><given-names>FE</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><name><surname>Khoury</surname><given-names>HJ</given-names></name><name><surname>Talpaz</surname><given-names>M</given-names></name><name><surname>DiPersio</surname><given-names>J</given-names></name><name><surname>DeAngelo</surname><given-names>DJ</given-names></name><name><surname>Abruzzese</surname><given-names>E</given-names></name><name><surname>Rea</surname><given-names>D</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>MÃ¼ller</surname><given-names>MC</given-names></name><name><surname>Gambacorti-Passerini</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>S</given-names></name><name><surname>Lustgarten</surname><given-names>S</given-names></name><name><surname>Rivera</surname><given-names>VM</given-names></name><name><surname>Clackson</surname><given-names>T</given-names></name><name><surname>Turner</surname><given-names>CD</given-names></name><name><surname>Haluska</surname><given-names>FG</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>Goldman</surname><given-names>JM</given-names></name><name><surname>Shah</surname><given-names>NP</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><collab>PACE Investigators</collab></person-group><year iso-8601-date="2013">2013</year><article-title>A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias</article-title><source>New England Journal of Medicine</source><volume>369</volume><fpage>1783</fpage><lpage>1796</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1306494</pub-id><pub-id pub-id-type="pmid">24180494</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>AD</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Drugging the undruggable RAS: Mission possible?</article-title><source>Nature Reviews Drug Discovery</source><volume>13</volume><fpage>828</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1038/nrd4389</pub-id><pub-id pub-id-type="pmid">25323927</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>DA</given-names></name><name><surname>Ashton</surname><given-names>SE</given-names></name><name><surname>Ghiorghiu</surname><given-names>S</given-names></name><name><surname>Eberlein</surname><given-names>C</given-names></name><name><surname>Nebhan</surname><given-names>CA</given-names></name><name><surname>Spitzler</surname><given-names>PJ</given-names></name><name><surname>Orme</surname><given-names>JP</given-names></name><name><surname>Finlay</surname><given-names>MR</given-names></name><name><surname>Ward</surname><given-names>RA</given-names></name><name><surname>Mellor</surname><given-names>MJ</given-names></name><name><surname>Hughes</surname><given-names>G</given-names></name><name><surname>Rahi</surname><given-names>A</given-names></name><name><surname>Jacobs</surname><given-names>VN</given-names></name><name><surname>Red Brewer</surname><given-names>M</given-names></name><name><surname>Ichihara</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Ballard</surname><given-names>P</given-names></name><name><surname>Al-Kadhimi</surname><given-names>K</given-names></name><name><surname>Rowlinson</surname><given-names>R</given-names></name><name><surname>Klinowska</surname><given-names>T</given-names></name><name><surname>Richmond</surname><given-names>GH</given-names></name><name><surname>Cantarini</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Ranson</surname><given-names>MR</given-names></name><name><surname>Pao</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>1046</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0337</pub-id><pub-id pub-id-type="pmid">24893891</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvorak</surname><given-names>P</given-names></name><name><surname>Dvorakova</surname><given-names>D</given-names></name><name><surname>Koskova</surname><given-names>S</given-names></name><name><surname>Vodinska</surname><given-names>M</given-names></name><name><surname>Najvirtova</surname><given-names>M</given-names></name><name><surname>Krekac</surname><given-names>D</given-names></name><name><surname>Hampl</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Expression and potential role of fibroblast growth factor 2 and its receptors in human embryonic stem cells</article-title><source>Stem Cells</source><volume>23</volume><fpage>1200</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1634/stemcells.2004-0303</pub-id><pub-id pub-id-type="pmid">15955829</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finlay</surname><given-names>MR</given-names></name><name><surname>Anderton</surname><given-names>M</given-names></name><name><surname>Ashton</surname><given-names>S</given-names></name><name><surname>Ballard</surname><given-names>P</given-names></name><name><surname>Bethel</surname><given-names>PA</given-names></name><name><surname>Box</surname><given-names>MR</given-names></name><name><surname>Bradbury</surname><given-names>RH</given-names></name><name><surname>Brown</surname><given-names>SJ</given-names></name><name><surname>Butterworth</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>A</given-names></name><name><surname>Chorley</surname><given-names>C</given-names></name><name><surname>Colclough</surname><given-names>N</given-names></name><name><surname>Cross</surname><given-names>DA</given-names></name><name><surname>Currie</surname><given-names>GS</given-names></name><name><surname>Grist</surname><given-names>M</given-names></name><name><surname>Hassall</surname><given-names>L</given-names></name><name><surname>Hill</surname><given-names>GB</given-names></name><name><surname>James</surname><given-names>D</given-names></name><name><surname>James</surname><given-names>M</given-names></name><name><surname>Kemmitt</surname><given-names>P</given-names></name><name><surname>Klinowska</surname><given-names>T</given-names></name><name><surname>Lamont</surname><given-names>G</given-names></name><name><surname>Lamont</surname><given-names>SG</given-names></name><name><surname>Martin</surname><given-names>N</given-names></name><name><surname>McFarland</surname><given-names>HL</given-names></name><name><surname>Mellor</surname><given-names>MJ</given-names></name><name><surname>Orme</surname><given-names>JP</given-names></name><name><surname>Perkins</surname><given-names>D</given-names></name><name><surname>Perkins</surname><given-names>P</given-names></name><name><surname>Richmond</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>RA</given-names></name><name><surname>Waring</surname><given-names>MJ</given-names></name><name><surname>Whittaker</surname><given-names>D</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Wrigley</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</article-title><source>Journal of Medicinal Chemistry</source><volume>57</volume><fpage>8249</fpage><lpage>8267</lpage><pub-id pub-id-type="doi">10.1021/jm500973a</pub-id><pub-id pub-id-type="pmid">25271963</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>SA</given-names></name><name><surname>Beare</surname><given-names>D</given-names></name><name><surname>Gunasekaran</surname><given-names>P</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Bindal</surname><given-names>N</given-names></name><name><surname>Boutselakis</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Cole</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Kok</surname><given-names>CY</given-names></name><name><surname>Jia</surname><given-names>M</given-names></name><name><surname>De</surname><given-names>T</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>COSMIC: exploring the world's knowledge of somatic mutations in human cancer</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>D805</fpage><lpage>D811</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1075</pub-id><pub-id pub-id-type="pmid">25355519</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fountas</surname><given-names>A</given-names></name><name><surname>Diamantopoulos</surname><given-names>LN</given-names></name><name><surname>Tsatsoulis</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tyrosine kinase inhibitors and diabetes: A novel treatment paradigm?</article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>26</volume><fpage>643</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2015.09.003</pub-id><pub-id pub-id-type="pmid">26492832</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greig</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Osimertinib: first global approval</article-title><source>Drugs</source><volume>76</volume><fpage>263</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1007/s40265-015-0533-4</pub-id><pub-id pub-id-type="pmid">26729184</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harskamp</surname><given-names>LR</given-names></name><name><surname>Gansevoort</surname><given-names>RT</given-names></name><name><surname>van Goor</surname><given-names>H</given-names></name><name><surname>Meijer</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The epidermal growth factor receptor pathway in chronic kidney diseases</article-title><source>Nature Reviews Nephrology</source><volume>12</volume><fpage>496</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2016.91</pub-id><pub-id pub-id-type="pmid">27374915</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Deininger</surname><given-names>M</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><name><surname>Lipton</surname><given-names>JH</given-names></name><name><surname>Goldberg</surname><given-names>SL</given-names></name><name><surname>Corm</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>NP</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Silver</surname><given-names>RT</given-names></name><name><surname>Niederwieser</surname><given-names>D</given-names></name><name><surname>Stone</surname><given-names>RM</given-names></name><name><surname>Dombret</surname><given-names>H</given-names></name><name><surname>Larson</surname><given-names>RA</given-names></name><name><surname>Roy</surname><given-names>L</given-names></name><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>MÃ¼ller</surname><given-names>MC</given-names></name><name><surname>Ezzeddine</surname><given-names>R</given-names></name><name><surname>Countouriotis</surname><given-names>AM</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib</article-title><source>Leukemia</source><volume>22</volume><fpage>1200</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1038/leu.2008.84</pub-id><pub-id pub-id-type="pmid">18401416</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hucthagowder</surname><given-names>V</given-names></name><name><surname>Meyer</surname><given-names>R</given-names></name><name><surname>Mullins</surname><given-names>C</given-names></name><name><surname>Nagarajan</surname><given-names>R</given-names></name><name><surname>DiPersio</surname><given-names>JF</given-names></name><name><surname>Vij</surname><given-names>R</given-names></name><name><surname>Tomasson</surname><given-names>MH</given-names></name><name><surname>Kulkarni</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma</article-title><source>Cancer Genetics</source><volume>205</volume><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.cancergen.2012.06.007</pub-id><pub-id pub-id-type="pmid">22939401</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>InglÃ©s-Prieto</surname><given-names>Ã</given-names></name><name><surname>Reichhart</surname><given-names>E</given-names></name><name><surname>Muellner</surname><given-names>MK</given-names></name><name><surname>Nowak</surname><given-names>M</given-names></name><name><surname>Nijman</surname><given-names>SM</given-names></name><name><surname>Grusch</surname><given-names>M</given-names></name><name><surname>Janovjak</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Light-assisted small-molecule screening against protein kinases</article-title><source>Nature Chemical Biology</source><volume>11</volume><fpage>952</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1933</pub-id><pub-id pub-id-type="pmid">26457372</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer</article-title><source>Translational Lung Cancer Research</source><volume>3</volume><fpage>370</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.3978/j.issn.2218-6751.2014.08.02</pub-id><pub-id pub-id-type="pmid">25806323</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kant</surname><given-names>SG</given-names></name><name><surname>Cervenkova</surname><given-names>I</given-names></name><name><surname>Balek</surname><given-names>L</given-names></name><name><surname>Trantirek</surname><given-names>L</given-names></name><name><surname>Santen</surname><given-names>GW</given-names></name><name><surname>de Vries</surname><given-names>MC</given-names></name><name><surname>van Duyvenvoorde</surname><given-names>HA</given-names></name><name><surname>van der Wielen</surname><given-names>MJ</given-names></name><name><surname>Verkerk</surname><given-names>AJ</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Hannema</surname><given-names>SE</given-names></name><name><surname>Wit</surname><given-names>JM</given-names></name><name><surname>Oostdijk</surname><given-names>W</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name><name><surname>Losekoot</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A novel variant of FGFR3 causes proportionate short stature</article-title><source>European Journal of Endocrinology</source><volume>172</volume><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1530/EJE-14-0945</pub-id><pub-id pub-id-type="pmid">25777271</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krejci</surname><given-names>P</given-names></name><name><surname>Murakami</surname><given-names>S</given-names></name><name><surname>Prochazkova</surname><given-names>J</given-names></name><name><surname>Trantirek</surname><given-names>L</given-names></name><name><surname>Chlebova</surname><given-names>K</given-names></name><name><surname>Ouyang</surname><given-names>Z</given-names></name><name><surname>Aklian</surname><given-names>A</given-names></name><name><surname>Smutny</surname><given-names>J</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Kozubik</surname><given-names>A</given-names></name><name><surname>Wilcox</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>20644</fpage><lpage>20653</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.083626</pub-id><pub-id pub-id-type="pmid">20439987</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krejci</surname><given-names>P</given-names></name><name><surname>Pejchalova</surname><given-names>K</given-names></name><name><surname>Wilcox</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway</article-title><source>Investigational New Drugs</source><volume>25</volume><fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1007/s10637-007-9054-7</pub-id><pub-id pub-id-type="pmid">17458503</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>KrutÃ¡</surname><given-names>M</given-names></name><name><surname>Å eneklovÃ¡</surname><given-names>M</given-names></name><name><surname>RaÅ¡ka</surname><given-names>J</given-names></name><name><surname>Salykin</surname><given-names>A</given-names></name><name><surname>ZerzÃ¡nkovÃ¡</surname><given-names>L</given-names></name><name><surname>PeÅ¡l</surname><given-names>M</given-names></name><name><surname>BÃ¡rtovÃ¡</surname><given-names>E</given-names></name><name><surname>Franek</surname><given-names>M</given-names></name><name><surname>BaumeisterovÃ¡</surname><given-names>A</given-names></name><name><surname>KoÅ¡kovÃ¡</surname><given-names>S</given-names></name><name><surname>Neelsen</surname><given-names>KJ</given-names></name><name><surname>Hampl</surname><given-names>A</given-names></name><name><surname>DvoÅÃ¡k</surname><given-names>P</given-names></name><name><surname>Rotrekl</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mutation frequency dynamics in HPRT locus in culture-adapted human embryonic stem cells and induced pluripotent stem cells correspond to their differentiated counterparts</article-title><source>Stem Cells and Development</source><volume>23</volume><fpage>2443</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.1089/scd.2013.0611</pub-id><pub-id pub-id-type="pmid">24836366</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>T</given-names></name><name><surname>Kuroda</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Kokubu</surname><given-names>A</given-names></name><name><surname>Okada</surname><given-names>N</given-names></name><name><surname>Hosoda</surname><given-names>F</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Taniguchi</surname><given-names>H</given-names></name><name><surname>Yanagihara</surname><given-names>K</given-names></name><name><surname>Imoto</surname><given-names>I</given-names></name><name><surname>Inazawa</surname><given-names>J</given-names></name><name><surname>Hirohashi</surname><given-names>S</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer</article-title><source>Carcinogenesis</source><volume>30</volume><fpage>1857</fpage><lpage>1864</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp206</pub-id><pub-id pub-id-type="pmid">19734198</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kweon</surname><given-names>SM</given-names></name><name><surname>Cho</surname><given-names>YJ</given-names></name><name><surname>Minoo</surname><given-names>P</given-names></name><name><surname>Groffen</surname><given-names>J</given-names></name><name><surname>Heisterkamp</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Activity of the Bcr GTPase-activating domain is regulated through direct protein/protein interaction with the Rho guanine nucleotide dissociation inhibitor</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>3023</fpage><lpage>3030</lpage><pub-id pub-id-type="doi">10.1074/jbc.M705513200</pub-id><pub-id pub-id-type="pmid">18070886</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laederich</surname><given-names>MB</given-names></name><name><surname>Horton</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>FGFR3 targeting strategies for achondroplasia</article-title><source>Expert Reviews in Molecular Medicine</source><volume>14</volume><elocation-id>e11</elocation-id><pub-id pub-id-type="doi">10.1017/erm.2012.4</pub-id><pub-id pub-id-type="pmid">22559284</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmon</surname><given-names>MA</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cell signaling by receptor tyrosine kinases</article-title><source>Cell</source><volume>141</volume><fpage>1117</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.06.011</pub-id><pub-id pub-id-type="pmid">20602996</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loots</surname><given-names>GG</given-names></name><name><surname>Ovcharenko</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>rVISTA 2.0: evolutionary analysis of transcription factor binding sites</article-title><source>Nucleic Acids Research</source><volume>32</volume><fpage>W217</fpage><lpage>W221</lpage><pub-id pub-id-type="doi">10.1093/nar/gkh383</pub-id><pub-id pub-id-type="pmid">15215384</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meloche</surname><given-names>S</given-names></name><name><surname>PouyssÃ©gur</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition</article-title><source>Oncogene</source><volume>26</volume><fpage>3227</fpage><lpage>3239</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210414</pub-id><pub-id pub-id-type="pmid">17496918</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modugno</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>New resistance mechanisms for small molecule kinase inhibitors of Abl kinase</article-title><source>Drug Discovery Today: Technologies</source><volume>11</volume><fpage>5</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2013.12.001</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naski</surname><given-names>MC</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ornitz</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia</article-title><source>Nature Genetics</source><volume>13</volume><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1038/ng0696-233</pub-id><pub-id pub-id-type="pmid">8640234</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>Q</given-names></name><name><surname>Titov</surname><given-names>DV</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Analyzing protein kinase dynamics in living cells with FRET reporters</article-title><source>Methods</source><volume>40</volume><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2006.06.013</pub-id><pub-id pub-id-type="pmid">16908183</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notredame</surname><given-names>C</given-names></name><name><surname>Higgins</surname><given-names>DG</given-names></name><name><surname>Heringa</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>T-Coffee: a novel method for fast and accurate multiple sequence alignment</article-title><source>Journal of Molecular Biology</source><volume>302</volume><fpage>205</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2000.4042</pub-id><pub-id pub-id-type="pmid">10964570</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passos-Bueno</surname><given-names>MR</given-names></name><name><surname>Wilcox</surname><given-names>WR</given-names></name><name><surname>Jabs</surname><given-names>EW</given-names></name><name><surname>SertiÃ©</surname><given-names>AL</given-names></name><name><surname>Alonso</surname><given-names>LG</given-names></name><name><surname>Kitoh</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Clinical spectrum of fibroblast growth factor receptor mutations</article-title><source>Human Mutation</source><volume>14</volume><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-1004(1999)14:2&lt;115::AID-HUMU3&gt;3.0.CO;2-2</pub-id><pub-id pub-id-type="pmid">10425034</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regot</surname><given-names>S</given-names></name><name><surname>Hughey</surname><given-names>JJ</given-names></name><name><surname>Bajar</surname><given-names>BT</given-names></name><name><surname>Carrasco</surname><given-names>S</given-names></name><name><surname>Covert</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>High-sensitivity measurements of multiple kinase activities in live single cells</article-title><source>Cell</source><volume>157</volume><fpage>1724</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.04.039</pub-id><pub-id pub-id-type="pmid">24949979</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scuto</surname><given-names>A</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name><name><surname>Popplewell</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kujawski</surname><given-names>M</given-names></name><name><surname>Kowolik</surname><given-names>C</given-names></name><name><surname>Xin</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kretzner</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wilcox</surname><given-names>WR</given-names></name><name><surname>Yen</surname><given-names>Y</given-names></name><name><surname>Forman</surname><given-names>S</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival</article-title><source>Leukemia</source><volume>25</volume><fpage>538</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/leu.2010.289</pub-id><pub-id pub-id-type="pmid">21164517</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ten Freyhaus</surname><given-names>H</given-names></name><name><surname>Dumitrescu</surname><given-names>D</given-names></name><name><surname>Berghausen</surname><given-names>E</given-names></name><name><surname>Vantler</surname><given-names>M</given-names></name><name><surname>Caglayan</surname><given-names>E</given-names></name><name><surname>Rosenkranz</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Imatinib mesylate for the treatment of pulmonary arterial hypertension</article-title><source>Expert Opinion on Investigational Drugs</source><volume>21</volume><fpage>119</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1517/13543784.2012.632408</pub-id><pub-id pub-id-type="pmid">22074410</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cancer genome landscapes</article-title><source>Science</source><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id><pub-id pub-id-type="pmid">23539594</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Santiago</surname><given-names>FS</given-names></name><name><surname>Janes</surname><given-names>M</given-names></name><name><surname>Kavurma</surname><given-names>MM</given-names></name><name><surname>Chong</surname><given-names>BH</given-names></name><name><surname>Pimanda</surname><given-names>JE</given-names></name><name><surname>Khachigian</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Phosphorylation and acetylation of histone H3 and autoregulation by early growth response 1 mediate interleukin 1beta induction of early growth response 1 transcription</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>30</volume><fpage>536</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.109.193821</pub-id><pub-id pub-id-type="pmid">20018936</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendt</surname><given-names>DJ</given-names></name><name><surname>Dvorak-Ewell</surname><given-names>M</given-names></name><name><surname>Bullens</surname><given-names>S</given-names></name><name><surname>Lorget</surname><given-names>F</given-names></name><name><surname>Bell</surname><given-names>SM</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Castillo</surname><given-names>S</given-names></name><name><surname>Aoyagi-Scharber</surname><given-names>M</given-names></name><name><surname>O'Neill</surname><given-names>CA</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name><name><surname>Wilcox</surname><given-names>WR</given-names></name><name><surname>Rimoin</surname><given-names>DL</given-names></name><name><surname>Bunting</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism</article-title><source>Journal of Pharmacology and Experimental Therapeutics</source><volume>353</volume><fpage>132</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1124/jpet.114.218560</pub-id><pub-id pub-id-type="pmid">25650377</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SH</given-names></name><name><surname>Sharrocks</surname><given-names>AD</given-names></name><name><surname>Whitmarsh</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Transcriptional regulation by the MAP kinase signaling cascades</article-title><source>Gene</source><volume>320</volume><fpage>3</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(03)00816-3</pub-id><pub-id pub-id-type="pmid">14597384</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname> <given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>HT</given-names></name><name><surname>Groffen</surname><given-names>J</given-names></name><name><surname>Heisterkamp</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Bcr/Abl P190 interaction with Spa-1, a GTPase activating protein for the small GTPase Rap1</article-title><source>International Journal of Molecular Medicine</source><volume>22</volume><fpage>453</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.3892/ijmm_00000042</pub-id><pub-id pub-id-type="pmid">18813851</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yosaatmadja</surname><given-names>Y</given-names></name><name><surname>Silva</surname><given-names>S</given-names></name><name><surname>Dickson</surname><given-names>JM</given-names></name><name><surname>Patterson</surname><given-names>AV</given-names></name><name><surname>Smaill</surname><given-names>JB</given-names></name><name><surname>Flanagan</surname><given-names>JU</given-names></name><name><surname>McKeage</surname><given-names>MJ</given-names></name><name><surname>Squire</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed</article-title><source>Journal of Structural Biology</source><volume>192</volume><fpage>539</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2015.10.018</pub-id><pub-id pub-id-type="pmid">26522274</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Ghaffari</surname><given-names>S</given-names></name><name><surname>Lodish</surname><given-names>H</given-names></name><name><surname>Malashkevich</surname><given-names>VN</given-names></name><name><surname>Kim</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Structure of the Bcr-Abl oncoprotein oligomerization domain</article-title><source>Nature structural biology</source><volume>9</volume><fpage>117</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/nsb747</pub-id><pub-id pub-id-type="pmid">11780146</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.21536.023</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewing editor</role><aff id="aff7"><institution>University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;One reporter for in-cell activity profiling of majority of protein kinase oncogenes&quot; for consideration by <italic>eLife</italic>. Your article has been favorably evaluated by Tony Hunter as the Senior Editor and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The authors describe an optimized EGR1-based reporter that can be used to measure the activity of many receptor tyrosine kinases. The strength of the system is that activity can be used in living cells and that it is amenable to high throughput screening. It is therefore likely that the reporter will be useful for many investigators.</p><p>Essential revisions:</p><p>1) Can the output of different kinases be quantitatively compared using this EGR1-driven reporter?</p><p>2) To what extent do different kinases turn on EGR1? Is it possible to normalize for extent of expression and specific activity of the overexpressed kinase?</p><p>3) FGFR inhibitors only partially block reporter activity caused by FGFR. Is this because of autocrine growth factor production and activation of ERK by another pathway? How does this limit the usefulness of the reporter?</p><p>4) The use of over expression in 293T cells to provide ligand-independent signaling is potentially a problem because the constitutive activity of these ligand-regulated receptors may not reflect their physiological or pathophysiological activity? Thus, while the reporter assay may be useful for identifying inhibitors, one wonders if it may be limited in other regards. This issue deserves some comment.</p><p>5) The authors point to the uncertainty surrounding the clinical toxicity of the BCR-ABL inhibitor ponatinib (subsection âpKrox24 reporters can be used to identify novel targets for clinically used kinase inhibitorsâ, first paragraph) as a potential use for their assay, but do not indicate whether their analysis of ponatinib reveals new targets that might explain the side effects arising from its ability to target other RTKs.</p><p>6) While the authors identify new targets for nilotinib (LTK and INSR), this discovery was made without the EGR1-based reporter. Inclusion of data for an application that utilized the EGR1-based reporter would be an effective way to demonstrate the utility of this system.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.21536.024</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>Essential revisions:</p><p><italic>1) Can the output of different kinases be quantitatively compared using this EGR1-driven reporter?</italic> </p><p>In <xref ref-type="fig" rid="fig1s4">Figure 1âfigure supplement 4</xref>, we used increasing concentrations of FGF-receptor (FGFR) ligand FGF2 to activate endogenous FGFR signaling in cells, in order to test to what extent the level of Krox24 transactivation correlates with differing levels of activation of endogenous FGFR signaling. We demonstrate that Krox24 transactivation gradually increases with 1-40 ng/ml FGF2, but peaks and plateaus at 40-100 ng/ml of FGF2. This suggests that the Krox24 reporters may have a limited capacity to quantitatively record the differences in RTK activation, especially in RTKs which are strong activators of ERK pathway, such as the FGFRs. In the manuscript revision, we tested the ability of Krox24 reporters to record differences in RTK activation by two experiments: (A) by determining whether different mutants belonging to one RTK transactivate Krox24 differently, corresponding to their known activity; (B) by determining whether the two groups of unrelated wt RTKs, belonging to strong or weak ERK activators, transactivate Krox24 reporters differently. The data presented by <xref ref-type="fig" rid="fig6">Author response image 1</xref> demonstrate that, in both cases, the relative differences in RTK activity can be distinguished by the levels of EGR1 expression and Krox24 reporter transactivation.<fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.21536.020</object-id><label>Author response image 1.</label><caption><p>(<bold>A</bold>) 293T cells were transfected with pKrox24 reporters together with empty vector and vectors expressing wild-type (WT) FGFR3 or its activating mutants G380R (associated with achondroplasia) and Y373C (associated with thanatophoric dysplasia). Note the differences in pKrox24 transactivation (upper graphs), and EGR1 induction (lower blot), which correspond to well documented differences in relative activity of the FGFR3 variants (see, for instance Krejci et al., PLoS <italic>ONE</italic>. 2008; 3: e3961), which is as follows: wt FGFR3&lt;G380R&lt;Y373C. K508M; kinase-dead FGFR3 mutant. (<bold>B</bold>) 293T cells were transfected with pKrox24 reporters together with empty vector and vectors expressing RTKs known to activate ERK pathway either weakly (INSR, IGF1R) or strongly (<italic>FGFR1</italic>, TRKB). Note the differences in pKrox24 transactivation (upper graphs), and EGR1 induction (lower blot), between strong and weak ERK activating RTKs. (Graphs) Values are averages from four biological replicates (each measured twice) with indicated S.D. Statistically significant differences are highlighted (Student's t-test; ***p&lt;0.001). The levels of RTK expression were quantified by western blot with V5 antibody (lower blot). Actin serves as the loading control.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.020">http://dx.doi.org/10.7554/eLife.21536.020</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-resp-fig1-v1"/></fig></p><p>We equipped all the RTKs and their mutants cloned for this project with C-terminal V5 epitope for easy monitoring of expression of different RTKs via western blot with single commercial V5 antibody. Experiment comparing the EGR1 induction and Krox24 transactivation by unrelated RTKs belonging to different families is shown by the <xref ref-type="fig" rid="fig6">Author response image 1</xref> above. We demonstrate that equally expressed (as determined by V5 western blot) FGFR1, TRKB, INSR and IGF1R induce different levels of EGR1 expression and Krox24 transactivation, corresponding to their known ability to activate ERK pathway. Using the tools developed here, it is therefore possible to directly compare to what levels the different RTKs activate the common pathways of downstream signal transduction.</p><p><italic>3) FGFR inhibitors only partially block reporter activity caused by FGFR. Is this because of autocrine growth factor production and activation of ERK by another pathway? How does this limit the usefulness of the reporter?</italic> </p><p>Manuscript <xref ref-type="fig" rid="fig1">Figure 1H, I</xref> demonstrates rather complete inhibition of Krox24 transactivation, mediated by FGFR3 transfection, with the cell treatment of FGFR inhibitor AZD1480. This is in contrast to data presented by <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5B</xref>, which show only partial AZD1480-mediated inhibition of Krox24 transactivation caused by high endogenous FGFR activity in hESC and hiPSC cells. The data presented elsewhere (Gudernova et al., 2016; Human Molecular Genetics, 25, 9-23), or those on <xref ref-type="fig" rid="fig7">Author response image 2</xref> demonstrate that AZD1480 is a potent FGFR inhibitor, capable of complete suppression of activation of even highly active <italic>FGFR1</italic>-3 mutants. Thus the residual Krox24 activity after AZD1480 treatment, as shown in <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5B</xref>, appears to be caused by ERK activation independent of FGFR signaling. This is no surprise since cultured cells usually have some levels of background ERK activity caused by serum growth factors. This fact could limit the use of Krox24 reporters in situations where the RTK transfection or activation of endogenous RTK signaling induces very little ERK activation on the top of high ERK background, and thus the two sources cannot be clearly distinguished from each other. Our data demonstrate that this is not the case for majority of the RTKs and their mutants tested here, which clearly induce EGR1 or transactivate Krox24 reporters when expressed in cells or endogenously, when activated by their cognate ligands (<xref ref-type="fig" rid="fig1">Figures 1A</xref>,<xref ref-type="fig" rid="fig4">4</xref>,<xref ref-type="fig" rid="fig5">5B</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplements 1</xref>, <xref ref-type="fig" rid="fig1s4">4</xref>, <xref ref-type="fig" rid="fig1s5">5A</xref>, <xref ref-type="fig" rid="fig1s8">8D</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1B</xref>; <xref ref-type="fig" rid="fig7">Author response image 2</xref>).<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.21536.021</object-id><label>Author response image 2.</label><caption><title>293T cells were transfected with empty vector or vector carrying the given FGFR variant, and treated with indicated AZD1480 for 24 hours.</title><p>FGFR activation was determined by detection of FGFR auto-phosphorylation (<bold>p</bold>) at Tyr653/654. Actin serves as the loading control. Control, untransfected cells. Note the efficient inhibition of FGFR activation with AZD1480, even in the case of highly active FGFR2 and FGFR3 mutants N550K and K650M, respectively.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.021">http://dx.doi.org/10.7554/eLife.21536.021</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-resp-fig2-v1"/></fig></p><p>In the manuscript, the reporter transactivation data presented by <xref ref-type="fig" rid="fig1">Figure 1A-G</xref> and <xref ref-type="fig" rid="fig1s4">Figure 1âfigure supplements 4</xref>, <xref ref-type="fig" rid="fig1s5">5A</xref>, <xref ref-type="fig" rid="fig1s7">7</xref> and <xref ref-type="fig" rid="fig1s8">8A, B, D</xref> were generated by treatment of three different cell types with fibroblast growth factor (FGF)-receptor ligand FGF2, and thus reflect the Krox24 reporter transactivation by endogenous FGFR signaling. In the revised manuscript, we evaluated the capacity of endogenous signaling of two other RTK families, EGFR and TRK, to transactivate Krox24 reporters. <xref ref-type="fig" rid="fig8">Author response image 3</xref> shows induction of EGR1 expression and transactivation of Krox24 reporters, mediated by endogenous EGFR signaling in 293T cells (activated by addition of EGF) or by endogenous TRK signaling in PC12 cells (activated by additions of NGF). Altogether, this demonstrates the capacity of Krox24 reporters to monitor the ligand-dependent activation of endogenous RTK signaling in cells.<fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.21536.022</object-id><label>Author response image 3.</label><caption><p>(<bold>A</bold>) 293T cells and (<bold>B</bold>) PC12 cells were transfected with pKrox24 reporters alone (293T) or together (PC12) with vector carrying <italic>Renilla</italic> luciferase under constant promoter (pRL-TK). Cells were treated with EGF (50 ng/ml) or NGF (100 ng/ml) for 24 hours before the level of Krox24 transactivation was determined by luciferase (<bold>A</bold>) or dual-luciferase (<bold>B</bold>) assay. Values are averages from four biological replicates (each measured twice) with indicated S.D. Statistically significant differences are highlighted (Student's t-test; ***p&lt;0.001). Results are representative for three independent experiments. The levels of EGR1 induction by EGF or NGF treatment were determined by western blot. Actin serves as the loading control.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.21536.022">http://dx.doi.org/10.7554/eLife.21536.022</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-21536-resp-fig3-v1"/></fig></p><p><italic>2) To what extent do different kinases turn on EGR1? Is it possible to normalize for extent of expression and specific activity of the overexpressed kinase?</italic> </p><p><italic>4) The use of over expression in 293T cells to provide ligand-independent signaling is potentially a problem because the constitutive activity of these ligand-regulated receptors may not reflect their physiological or pathophysiological activity? Thus, while the reporter assay may be useful for identifying inhibitors, one wonders if it may be limited in other regards. This issue deserves some comment.</italic> </p><p><italic>5) The authors point to the uncertainty surrounding the clinical toxicity of the BCR-ABL inhibitor ponatinib (subsection âpKrox24 reporters can be used to identify novel targets for clinically used kinase inhibitorsâ, first paragraph) as a potential use for their assay, but do not indicate whether their analysis of ponatinib reveals new targets that might explain the side effects arising from its ability to target other RTKs.</italic> </p><p>All clinically used BCR-ABL TKIs display some toxicity, which in the case of ponatinib resulted in recent discontinuation of the therapy. The analysis presented by manuscript <xref ref-type="fig" rid="fig5">Figure 5A</xref> reveals off-target activities for all five tested BCR-ABL TKIs, in agreement with the published literature (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1E</xref>). Compared to other TKIs, ponatinib inhibits the largest amount of RTKs, which may account for its side effects in the chronic myeloid leukemia therapy, which exceed those of other TKIs. We however did not discover any novel ponatinib targets, all RTKs found inhibited here were already reported in the literature (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1E</xref>). Instead, the experiments presented by <xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1E</xref> identified two new targets (LTK and INSR) for nilotinib. The revised manuscript text was updated to clearly indicate that, out of the five TKIs tested, novel targets were only identified for nilotinib (subsection âpKrox24 reporters can be used to identify novel targets for clinically used kinase inhibitorsâ, first paragraph).</p><p>We have chosen the BCR-ABL TKIs to demonstrate one possible application of the tools developed here because their off-target activities have been thoroughly evaluated before, and thus the published evidence may serve as a reference for estimation of the fidelity of developed screening assays. Our data demonstrate that the off-target activities of all five BCR-ABL TKIs found here match those previously reported, and that novel targets can be found even for the well-studied TKIs.</p><p><italic>6) While the authors identify new targets for nilotinib (LTK and INSR), this discovery was made without the EGR1-based reporter. Inclusion of data for an application that utilized the EGR1-based reporter would be an effective way to demonstrate the utility of this system.</italic></p><p>As suggested by published literature (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1E</xref>), nilotinib and other four BCR-ABL TKIs evaluated in the study (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>) inhibit many RTKs and thus any potential novel targets found in reporter screening would have to be validated and compared with known targets by independent and more precise experimental approach. To preserve time and resources, we therefore opted to skip the initial reporter screening and evaluated the TKI activity in experiments which allow determination of TKI effect on given RTK activity directly and in different TKI concentrations, as presented in <xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1B</xref>.</p><p>The experiments presented by <xref ref-type="fig" rid="fig5">Figure 5B</xref> utilize the EGR1-based reporter to discover LTK as a novel target of EGFR inhibitor osimertinib, demonstrating the utility of Krox24 reporters for finding new targets for RTK inhibitors already used in clinic.</p></body></sub-article></article>